Abstract
Reactivation of hepatitis B virus is a known complication of immunosuppressive therapy and may cause liver failure and even death. A twenty-year-old male patient visited the endocrinology department because of short stature and diagnosed as growth hormone deficient. Somatropin and cortisone acetate were initiated. After six months, HBV reactivation was occurred. Antiviral treatment with lamivudine was initiated after the increase in transaminases. After a six months’ initiating lamivudine therapy, his physical examination and laboratory test results were found to be normal. In conclusion, every patient who are planned to be received immunosuppressive therapy should be screened for HBV infection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
